Skip to content
Screener

Wave Life Sciences WVE Q1 2026 earnings

Reported April 28, 2026 · Before market open

Revenue$38.2MBeat by $29.8M
EPS-$0.13Beat by $0.21
Revenue estimate$8.5M
EPS estimate-$0.34

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$5.0M
EPS estimate-$0.33

Financials

Q1 2026

Income statement

See full
Revenue$38.2M+317%
Operating income-$31.3M+37.2%
Net income-$26.1M+44.4%
EPS (diluted)-$0.13+55.2%

Balance sheet

See full
Cash & equivalents$544.6M+124%
Total debt$15.7M-33.4%
Total equity$511.7M+198%
Total assets$583.5M+102%

Cash flow

See full
Operating cash flow-$59.6M+5.5%
CapEx$438.0K+165%
Free cash flow-$60.0M+5.1%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.36B+10.1%
Enterprise value$835.97M-18.1%

Returns & leverage

See full
Return on equity-53.7%—
Debt / equity0×-0.1×
Current ratio11.3×+8.3×

FAQ

When did Wave Life Sciences report Q1 2026 earnings?
Wave Life Sciences (WVE) reported Q1 2026 earnings on April 28, 2026 before market open.
What were Wave Life Sciences's Q1 2026 revenue and EPS?
Wave Life Sciences reported revenue of $38.2M and eps of $-0.13 for Q1 2026.
Did Wave Life Sciences beat estimates in Q1 2026?
Revenue beat the consensus estimate of $8.5M by $29.8M. EPS beat the consensus estimate of $-0.34 by $0.21.
How did Wave Life Sciences's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 316.9% from $9.2M a year earlier and eps grew 55.2% from $-0.29.
Where can I find Wave Life Sciences's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-183563) and the 10-Q periodic report (0001193125-26-183587) directly on SEC EDGAR. The filing index links above go to sec.gov.